Poseida Therapeutics, Inc. (Nasdaq: PSTX) is set to present new clinical and preclinical data on its allogeneic CAR-T cell therapies at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting and the 66th American Society of Hematology (ASH) Annual Meeting & Exposition. The data highlight advancements in treatments for both hematologic cancers and solid tumors, leveraging Poseida's proprietary genetic editing platforms.
SITC Presentation: Advancing Solid Tumor Targeting
At SITC, Poseida will present preclinical data on allogeneic CAR+TCR-T cells enriched with stem cell memory T cells (TSCM). These cells exhibit enhanced potency and improved targeting capabilities against solid tumors. The presentation, titled "Multi-antigen Targeting with CAR and TCR Co-expression in Allogeneic Cell Therapy for Solid Tumors," will be delivered by Sergio M. Quinones-Parra, Ph.D., on November 9, 2024.
ASH Presentations: Deepening Understanding of Hematologic Cancer Therapies
Poseida will also feature prominently at ASH with multiple poster presentations. One presentation will focus on additional profiling of patient responses from Arm C of the P-BCMA-ALLO1 Phase 1 study, which uses optimized lymphodepletion. Another presentation will cover preclinical data from the ongoing Phase 1 trial of P-CD19CD20-ALLO1 in patients with B-cell malignancies.
An interesting case study will be presented by Anupama Kumar, M.D., from UCSF, detailing a patient with relapsed multiple myeloma who experienced late polyclonal P-BCMA-101 CAR-T cell re-expansion and a rapid complete response after one cycle of talquetamab, more than three years post-CAR-T infusion.
P-BCMA-ALLO1: Targeting Multiple Myeloma
P-BCMA-ALLO1, an investigational non-viral TSCM-rich allogeneic CAR-T therapy targeting B-cell maturation antigen (BCMA), is currently in Phase 1/1b clinical development. It has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for adult patients with relapsed/refractory multiple myeloma after three or more prior lines of therapies. Interim clinical data presented at IMS in September 2024 supports the potential of TSCM-rich allogeneic CAR-Ts to offer effective, safe, and reliable treatment for multiple myeloma.
P-CD19CD20-ALLO1: Dual-Targeting for B-Cell Malignancies
P-CD19CD20-ALLO1, developed in partnership with Roche, is an allogeneic CAR-T cell therapy product candidate designed for relapsed or refractory B-cell malignancies. This therapy targets both CD19 and CD20 antigens, aiming to overcome antigen escape limitations associated with CD19-only targeted CAR-T therapies. Preclinical data suggests that P-CD19CD20-ALLO1 demonstrates superior efficacy compared to single-target products. The ongoing Phase 1 study is further evaluating its potential in treating B-cell malignancies.
